Genetic inhibition of CRMP2 phosphorylation at serine 522 promotes axonal regeneration after optic nerve injury

Scientific Reports, 2019 · DOI: 10.1038/s41598-019-43658-w · Published: May 13, 2019

Simple Explanation

Axonal degeneration is a problem in neurological diseases where nerve cells are damaged. The body's ability to repair these damaged nerve cells is limited by inhibitory factors in the central nervous system. This study looks at how inhibiting a specific protein called CRMP2 can help with nerve regeneration. The researchers used genetically modified mice where CRMP2 phosphorylation at Ser 522 is inhibited. They injured the optic nerve and observed that the mice with inhibited CRMP2 phosphorylation showed better axonal regeneration. The study suggests that inhibiting the phosphorylation of CRMP2 can suppress nerve cell degeneration and encourage the regeneration of axons after an optic nerve injury.

Study Duration

4 weeks

Participants

Adult male wild-type and CRMP2 KI mice aged between 10 and 16 weeks

Evidence Level

Not specified

Key Findings

1
Inhibition of CRMP2 phosphorylation suppresses microtubule depolymerization after optic nerve injury.
2
CRMP2 KI mice exhibited reduced retinal ganglion cell loss after optic nerve crush injury.
3
Increased numbers of axons labeled by a tracer were observed in the optic nerve after optic nerve crush in CRMP2 KI mice, indicating enhanced axonal regeneration.

Research Summary

This study investigates the role of CRMP2 phosphorylation in axonal regeneration after optic nerve injury using CRMP2 knock-in mice, where CRMP2 phosphorylation at Ser522 is inhibited. The results indicate that inhibition of CRMP2 phosphorylation suppresses microtubule depolymerization, reduces retinal ganglion cell loss, and promotes axonal regeneration after optic nerve injury. The findings suggest that inhibiting CRMP2 phosphorylation could be a novel therapeutic approach for treating human optic nerve injuries.

Practical Implications

Potential Therapeutic Target

Inhibition of CRMP2 phosphorylation can be a novel target for therapies aimed at treating optic nerve injuries and promoting axonal regeneration.

Drug Development

The study provides a rationale for developing drugs that can inhibit CRMP2 phosphorylation to promote nerve regeneration.

Combination Therapies

Additional treatments to facilitate myelination of regenerated axons may be needed for functional recovery after optic nerve injury.

Study Limitations

1
The study was conducted on mice, and the results may not be directly applicable to humans.
2
The molecular mechanisms by which CRMP2 promotes microtubule polymerization and actin bundling require further investigation.
3
The long-term effects of inhibiting CRMP2 phosphorylation on optic nerve regeneration and visual function were not evaluated.

Your Feedback

Was this summary helpful?

Back to Regenerative Medicine